Patents Represented by Attorney Herbert W. Taylor, Jr.
  • Patent number: 3974184
    Abstract: This invention relates to the novel compounds 3',5,7-trihydroxy-4',6-dimethoxy-isoflavone, 3'5,7-trihydroxy-4',8-dimethoxy-isoflavone and 3',7-dihydroxy-4',6,8-trimethoxy-isoflavone which are powerful inhibitors of catechol-O-methyl transferase (COMT) and to their production by fermentation of Actinomyces roseolus.
    Type: Grant
    Filed: July 23, 1974
    Date of Patent: August 10, 1976
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Hamao Umezawa, Tomio Takeuchi, Hideo Chimura, Tsutomu Sawa, Masa Hamada
  • Patent number: 3973038
    Abstract: Compounds having the general formula ##SPC1##(the meanings of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are indicated hereinafter) and the pharmaceutically acceptable salts and esters thereof exhibit strong activities in inhibiting histidine decarboxylase and xanthine oxidase.
    Type: Grant
    Filed: April 17, 1974
    Date of Patent: August 3, 1976
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Hamao Umezawa, Tomio Takeuchi, Akira Takamatsu, Kenji Kayahara
  • Patent number: 3959257
    Abstract: This invention relates to a process for the preparation of coformycin, 3-(.beta.-D-ribofuranosyl)-6,7,8-trihydroimidazo[4,5-d][1,3]diazepin-8(R)- ol, through a synthetic route from a new derivative of 9-.beta.-D-ribofuranosyl-purine and other synthetic intermediates involved in the process and their preparation.
    Type: Grant
    Filed: October 24, 1974
    Date of Patent: May 25, 1976
    Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai
    Inventors: Hamao Umezawa, Kenji Maeda, Shinichi Kondo
  • Patent number: 3952096
    Abstract: Calcium .alpha.-p-chlorophenoxyisobutyrate, particularly as its novel monohydrate, when combined with about one to two parts by weight of calcium carbonate in oral dosage form for use in mammals, and especially man, provides a safe and effective composition for reducing elevated blood levels of cholesterol, triglycerides and/or low density lipoproteins and/or increasing fibrinolytic activity and/or decreasing platelet aggregation. A preferred embodiment is a capsule containing 500 mgm. calcium carbonate and 250 or 500 mgm. crystalline calcium .alpha.-p-chlorophenoxyisobutyrate monohydrate having the empirical formula C.sub.10 H.sub.10 ClO.sub.3 Ca.sub.1/2.H.sub.2 O.
    Type: Grant
    Filed: June 15, 1973
    Date of Patent: April 20, 1976
    Assignee: Bristol-Myers Company
    Inventors: John Carl Godfrey, John Edwin MacNintch, Joseph Rubinfeld
  • Patent number: 3950352
    Abstract: The title compounds, which can also be called oxapenicillins G and V, are produced by chemical synthesis and then, if desired, are deacylated.
    Type: Grant
    Filed: August 26, 1974
    Date of Patent: April 13, 1976
    Assignee: Queen's University
    Inventor: Saul Wolfe
  • Patent number: 3948927
    Abstract: The title compound is produced by chemical synthesis and, if desired, converted as by N-phenylacetylation to a new .beta.-lactam antibiotic such as oxapenicillin G.
    Type: Grant
    Filed: August 12, 1974
    Date of Patent: April 6, 1976
    Assignee: Queen's University
    Inventor: Saul Wolfe
  • Patent number: 3946000
    Abstract: 7-[.alpha.-(2-Aminomethyl-1-cyclohexyl)-acetamido]-3-heterocyclic thiomethyl-3-cephem-4-carboxylic acids, and their nontoxic, pharmaceutically acceptable salts and their Schiff bases, as made by reaction of salicylaldehyde with the free amino group, are valuable as antibacterial agents and are particularly valuable as therapeutic agents in poultry and animals, including man, in the treatment of infectious diseases caused by many Gram-positive and Gram-negative bacteria.
    Type: Grant
    Filed: October 31, 1973
    Date of Patent: March 23, 1976
    Assignee: Bristol-Myers Company
    Inventors: Takayuki Naito, Jun Okumura, Hajime Kamachi